Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Эффективность Пронорана у пациентов с болезнью Паркинсона
Эффективность Пронорана у пациентов с болезнью Паркинсона
Пилипович А.А. Эффективность Пронорана у пациентов с болезнью Паркинсона. Consilium Medicum. 2014; 16 (9): 5–10.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Ziegler M, Caldas A, Del Signore et al. Efficacy of piribedil in Acinetic-Hypertonic Parcinsonian Patients after 4-Month Combination Treatment with L-Dopa. Parkinsonism and related disorders 2001; 7: 75.
2. Cagnotto A, Parotti L, Mennini T. In vitro affinity of piribedil for dopamine D3 receptor subtypes, an autoradiographic study. Eur
J Pharmacol 1996; p. 63–7.
3. Федорова Н.В., Ким И.П. Лечение болезни Паркинсона. Журн. неврологии и психиатрии. 2002; 2: 68–75.
4. Ziegler M, Rondot P. Activity of piribedil in Parkinson’s diseas: a multicenter study. Presse Med 1999; 28: 1414–8.
5. Pagliary R, Peyrin L, Crambes O. Differential regional and kinetics effects of piribedil and bromocriptine on dopamine metabolites: a brain microdialysis study in freely moving rats. J Neurol Transm 1995; 101: 13–26.
6. Millan MJ, Cussac D, Milligan G et al. Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterization. J Pharmacol Exp Ther 2001; 297: 876–87.
7. Федорова Н. В., Артемьева Е.Г. Применение пронорана – современного агониста дофаминовых рецепторов в лечении болезни Паркинсона. Информационное письмо. М., 2003.
8. Ziegler M, Rascol O. Efficacy of piribedil in adjunction to L-dopa in a 6-month rundomized placebo-controlled study in early Parkinson’s diseases. 52 Annual Meeting of the American Academy of Neurology. San Diego, 2000; Abstract.
9. Allain H, Coz F, Del Signore S et al. Piribedil Plasma Levels after Chronic Oral Administration of Trivastal Retard 50 (150 mg/day) in Parkinsonian Patients. Parkinsonism and related disorders 2001; 7: 51.
10. Ziegler M, Del Signore S, Bonhomme C et al. Resting Tremor is Inversely Related to Piribedil Plasma Concentration after Intravenous Administration in Parkinsonian Patients. Parkinsonism and related disorders 2001; 7: 75.
11. Agnoli A, Baldassarini M, Del Roscio et al. Piribedil and Parkinson’s disease: Protection of Peripheral Side-Effects by Domperidone. Apomorphine and Other Dopaminagonistics. Clin Pharmocol 1981; 2: 117–22.
12. Rondot P, Ziegler M. Activity and acceptability of piribedil in Parkinson’s disease: a multicentre study. J Neurol 1992; 239: 28–34.
13. Pagliary R, Peyrin L, Crambes O. Differential regional and kinetics effects of piribedil and bromocriptine on dopamine metabolites: a brain microdialysis study in freely moving rats. J Neurol Transm 1995; 101: 13–26.
14. Ziegler M, Caldas A, Del Signore et al. Efficacy of piribedil in Acinetic-Hypertonic Parcinsonian Patients after 4-Month Combination Treatment with L-Dopa. Parkinsonism and related disorders 2001; 7: 75.
15. Salazar T. Efficacy of piribedil in adjunction to L-dopa in Parcinson’s disease. Venezuelian experience. 6th International Congress on Parkinson’s Disease and Movement disorders. Barcelona, June 2000; Abstract.
16. Tolosa ES, Valldeoriola F, Marti MJ. New and emerging strategies for improving levodopa treatment. Neurology 1994; 44: 35–44.
17. Engel J, Granerus A, Savanborg A. Piribedil in Parkinson’s syndrome: a clinical study. Eur J Clin Pharmacol 1975; 8: 223–6.
18. Захаров В.В. Всероссийская программа исследований эпидемиологии и терапии когнитивных расстройств в пожилом возрасте («Прометей»). Неврологический журн. 2006; 11: 27–32.
19. Яхно Н.Н., Захаров В.В.. Страчунская Е.Я. и др. Лечение недементных когнитивных нарушений у пациентов с артериальной гипертензией и церебральным атеросклерозом. (По результатам российского мультицентрового исследования ФУЭТЕ.) Неврологический журн. 2012; 4: 49–55.
20. Nagaraja D, Jayashree S. Randomized study of the dopamine receptor agonist piribedil in the treatment of mild cognitive impairment. Am J Psychiatry 2001; 158 (9): 1517–9.
21. Ollat H. Dopaminergic insufficiency reflecting cerebral ageing: value of a dopaminergic agonist, piribedil. J Neurol 1992; 23: 13–6.
22. Pirozzolo FJ, Hansch EC, Mortimer JA et al. Dementhia in Parkinson’s diseases: a neuropsychological analysis. Brain Cogn 1982; 1: 71–83.
23. Tandberg E, Larsen JP, Karlsen K. Excessive daytime sleepiness and sleep benefit in Parkinson’s diseases: community based study. Mov Disord 1999; 14: 71–83.
24. Corbe C, Arnaud F, Brault Y et al. Effect of a dopaminergic agonist, piribedil (Trivastal 50 mg LP), on visual and spatial integration in elderly subjects. J Neurol 1992; 239: 22–7.
25. Lassare P, Coppolani T. National multicenter trial in 6000 patients of trivastal retard, 1 tablet per day, in treatment of cerebral insufficiency. Vie Med 1980; 61: 39–50.
26. Steriade M, Gloor P, Llinas R et al. Basic mechanisms of cerebral rhythmic activities. Electroencephalogr Clin Neurophysyol 1990; 76: 481–508.
2. Cagnotto A, Parotti L, Mennini T. In vitro affinity of piribedil for dopamine D3 receptor subtypes, an autoradiographic study. Eur
J Pharmacol 1996; p. 63–7.
3. Федорова Н.В., Ким И.П. Лечение болезни Паркинсона. Журн. неврологии и психиатрии. 2002; 2: 68–75.
4. Ziegler M, Rondot P. Activity of piribedil in Parkinson’s diseas: a multicenter study. Presse Med 1999; 28: 1414–8.
5. Pagliary R, Peyrin L, Crambes O. Differential regional and kinetics effects of piribedil and bromocriptine on dopamine metabolites: a brain microdialysis study in freely moving rats. J Neurol Transm 1995; 101: 13–26.
6. Millan MJ, Cussac D, Milligan G et al. Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterization. J Pharmacol Exp Ther 2001; 297: 876–87.
7. Федорова Н. В., Артемьева Е.Г. Применение пронорана – современного агониста дофаминовых рецепторов в лечении болезни Паркинсона. Информационное письмо. М., 2003.
8. Ziegler M, Rascol O. Efficacy of piribedil in adjunction to L-dopa in a 6-month rundomized placebo-controlled study in early Parkinson’s diseases. 52 Annual Meeting of the American Academy of Neurology. San Diego, 2000; Abstract.
9. Allain H, Coz F, Del Signore S et al. Piribedil Plasma Levels after Chronic Oral Administration of Trivastal Retard 50 (150 mg/day) in Parkinsonian Patients. Parkinsonism and related disorders 2001; 7: 51.
10. Ziegler M, Del Signore S, Bonhomme C et al. Resting Tremor is Inversely Related to Piribedil Plasma Concentration after Intravenous Administration in Parkinsonian Patients. Parkinsonism and related disorders 2001; 7: 75.
11. Agnoli A, Baldassarini M, Del Roscio et al. Piribedil and Parkinson’s disease: Protection of Peripheral Side-Effects by Domperidone. Apomorphine and Other Dopaminagonistics. Clin Pharmocol 1981; 2: 117–22.
12. Rondot P, Ziegler M. Activity and acceptability of piribedil in Parkinson’s disease: a multicentre study. J Neurol 1992; 239: 28–34.
13. Pagliary R, Peyrin L, Crambes O. Differential regional and kinetics effects of piribedil and bromocriptine on dopamine metabolites: a brain microdialysis study in freely moving rats. J Neurol Transm 1995; 101: 13–26.
14. Ziegler M, Caldas A, Del Signore et al. Efficacy of piribedil in Acinetic-Hypertonic Parcinsonian Patients after 4-Month Combination Treatment with L-Dopa. Parkinsonism and related disorders 2001; 7: 75.
15. Salazar T. Efficacy of piribedil in adjunction to L-dopa in Parcinson’s disease. Venezuelian experience. 6th International Congress on Parkinson’s Disease and Movement disorders. Barcelona, June 2000; Abstract.
16. Tolosa ES, Valldeoriola F, Marti MJ. New and emerging strategies for improving levodopa treatment. Neurology 1994; 44: 35–44.
17. Engel J, Granerus A, Savanborg A. Piribedil in Parkinson’s syndrome: a clinical study. Eur J Clin Pharmacol 1975; 8: 223–6.
18. Захаров В.В. Всероссийская программа исследований эпидемиологии и терапии когнитивных расстройств в пожилом возрасте («Прометей»). Неврологический журн. 2006; 11: 27–32.
19. Яхно Н.Н., Захаров В.В.. Страчунская Е.Я. и др. Лечение недементных когнитивных нарушений у пациентов с артериальной гипертензией и церебральным атеросклерозом. (По результатам российского мультицентрового исследования ФУЭТЕ.) Неврологический журн. 2012; 4: 49–55.
20. Nagaraja D, Jayashree S. Randomized study of the dopamine receptor agonist piribedil in the treatment of mild cognitive impairment. Am J Psychiatry 2001; 158 (9): 1517–9.
21. Ollat H. Dopaminergic insufficiency reflecting cerebral ageing: value of a dopaminergic agonist, piribedil. J Neurol 1992; 23: 13–6.
22. Pirozzolo FJ, Hansch EC, Mortimer JA et al. Dementhia in Parkinson’s diseases: a neuropsychological analysis. Brain Cogn 1982; 1: 71–83.
23. Tandberg E, Larsen JP, Karlsen K. Excessive daytime sleepiness and sleep benefit in Parkinson’s diseases: community based study. Mov Disord 1999; 14: 71–83.
24. Corbe C, Arnaud F, Brault Y et al. Effect of a dopaminergic agonist, piribedil (Trivastal 50 mg LP), on visual and spatial integration in elderly subjects. J Neurol 1992; 239: 22–7.
25. Lassare P, Coppolani T. National multicenter trial in 6000 patients of trivastal retard, 1 tablet per day, in treatment of cerebral insufficiency. Vie Med 1980; 61: 39–50.
26. Steriade M, Gloor P, Llinas R et al. Basic mechanisms of cerebral rhythmic activities. Electroencephalogr Clin Neurophysyol 1990; 76: 481–508.
Авторы
А.А.Пилипович
Кафедра нервных болезней ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава России
Кафедра нервных болезней ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава России
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.